SU2C and Genentech announced a Catalyst collaboration aimed at accelerating the development of new cancer treatments and combination therapies by providing funding and access to a dozen of the company’s medicines.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
